Can mTOR inhibitors reduce the risk of late kidney allograft failure? - Wikidata - awgldk - TriplyDB

Can mTOR inhibitors reduce the risk of late kidney allograft failure?

Can mTOR inhibitors reduce the risk of late kidney allograft failure?

http://www.wikidata.org/entity/Q36884566

about

Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model mTOR: taking cues from the immune microenvironment.Efficacy and safety of low-dose everolimus as maintenance immunosuppression in cardiac transplant recipients.

P2860

Q28731390-E89EBBD6-F189-484E-8313-7A2C9B437469 Q37552045-EC31B7FA-7BBE-4364-8BE3-43F31F2D9877 Q42009158-D9688999-E3A0-45C4-AC55-FF7E4AC331AF

P2860

Can mTOR inhibitors reduce the risk of late kidney allograft failure?

http://www.wikidata.org/entity/Q36884566

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Can mTOR inhibitors reduce the risk of late kidney allograft failure?

@en

type

label

Can mTOR inhibitors reduce the risk of late kidney allograft failure?

@en

prefLabel

Can mTOR inhibitors reduce the risk of late kidney allograft failure?

@en

P1433

Q36884566-455CDE22-B450-4C2F-88A6-E6D89EB978D3

P1476

Q36884566-822B5C62-C023-4D3C-8D4B-480F1E676011

P2093

Q36884566-5DC7D5BF-B057-4C25-B1D8-17FCDDC4452F

P2860

Q36884566-02C929CF-C26B-45E7-A4B3-7E24F2399865

Q36884566-0950CB49-E727-478F-8E8C-131416C63B3A

Q36884566-0D9D97FD-1931-477C-ACAE-290D79C89483

Q36884566-11B4C5B1-AFFC-4BC7-AFE4-C721A7BB59C4

Q36884566-140AC7CE-16AB-4A4F-9993-DD4B6555B193

Q36884566-19BE3C9A-378F-4E32-B5B9-768A0FEDD1ED

Q36884566-1DE8B6AD-267F-4E30-A676-93142A8B96AA

Q36884566-1E44201E-DCDD-47F4-8C30-4C48FBBA865F

Q36884566-1E69B22F-E188-4541-B305-D66BAD941323

Q36884566-1FCCF8ED-26A7-437D-8A8C-8C9257A56999

P304

Q36884566-EF20F8F1-9C44-483A-A876-1B83441E0696

P31

Q36884566-57EB0C30-95C8-4E60-828B-09C31D208D1B

P356

Q36884566-275F7ADD-99F3-4FF5-9C1D-D82A422C3D28

P433

Q36884566-2E54909D-60A9-40CE-AC12-28AF5420C11F

P478

Q36884566-1024E3F7-C71F-4FED-BAD2-6B8B8FF39332

P577

Q36884566-8DD96305-AF0D-4671-8E7F-EDA95414AB80

P5875

Q36884566-3A342693-CD69-4BA1-9315-8F04107C4B5C

P698

Q36884566-EE30760F-15CC-4D01-83C5-350C118E7218

P356

J.1432-2277.2007.00524.X

P1433

Transplant International

P1476

Can mTOR inhibitors reduce the risk of late kidney allograft failure?

@en

P2093

Claudio Ponticelli

http://www.w3.org/2001/XMLSchema#string

P2860

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Coronary-artery stents

Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years.

Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients.

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.

The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

Post-transplant malignancy: the role of immunosuppression.

Infection in organ-transplant recipients.

P304

2-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1432-2277.2007.00524.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2007-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6202304

http://www.w3.org/2001/XMLSchema#string

P698

17635837

http://www.w3.org/2001/XMLSchema#string